Jan 04th 2013 - Edison Investment Research today published a report on Onyx Pharmaceuticals entitled "DECISION Made". In summary, the report says:
The positive outcome of the Phase III trial, DECISION, should have an immediate impact on Nexavar’s revenue growth, which was relatively flat in the last few quarters and expected to remain so due to sales from the drug’s approved indications peaking. Additional revenue could be in the $200m to $250m range worldwide for radioactive iodine-refractory (RAI) differentiated thyroid cancer (DTC), a condition currently without approved systematic treatment options.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »